JP5804459B2 - 癌疾患用細胞老化促進剤 - Google Patents
癌疾患用細胞老化促進剤 Download PDFInfo
- Publication number
- JP5804459B2 JP5804459B2 JP2011547497A JP2011547497A JP5804459B2 JP 5804459 B2 JP5804459 B2 JP 5804459B2 JP 2011547497 A JP2011547497 A JP 2011547497A JP 2011547497 A JP2011547497 A JP 2011547497A JP 5804459 B2 JP5804459 B2 JP 5804459B2
- Authority
- JP
- Japan
- Prior art keywords
- mir
- cells
- hsa
- cell
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010028980 Neoplasm Diseases 0.000 title claims description 103
- 201000011510 cancer Diseases 0.000 title claims description 98
- 230000032677 cell aging Effects 0.000 title claims description 29
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 12
- 108091070494 Homo sapiens miR-22 stem-loop Proteins 0.000 claims description 151
- 108091062170 Mir-22 Proteins 0.000 claims description 113
- 108090000623 proteins and genes Proteins 0.000 claims description 81
- 230000032683 aging Effects 0.000 claims description 65
- 206010006187 Breast cancer Diseases 0.000 claims description 25
- 208000026310 Breast neoplasm Diseases 0.000 claims description 25
- 206010027476 Metastases Diseases 0.000 claims description 22
- 230000009401 metastasis Effects 0.000 claims description 21
- 230000009758 senescence Effects 0.000 claims description 20
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 13
- 230000009400 cancer invasion Effects 0.000 claims description 10
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 9
- 239000004480 active ingredient Substances 0.000 claims description 9
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 8
- 201000010881 cervical cancer Diseases 0.000 claims description 8
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 6
- 206010017758 gastric cancer Diseases 0.000 claims description 6
- 201000011549 stomach cancer Diseases 0.000 claims description 6
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 claims description 4
- 206010034811 Pharyngeal cancer Diseases 0.000 claims description 4
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 4
- 208000029742 colonic neoplasm Diseases 0.000 claims description 4
- 206010046766 uterine cancer Diseases 0.000 claims description 4
- 230000001737 promoting effect Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 369
- 238000000034 method Methods 0.000 description 91
- 230000014509 gene expression Effects 0.000 description 72
- 241000282414 Homo sapiens Species 0.000 description 65
- 108091070501 miRNA Proteins 0.000 description 62
- 210000002950 fibroblast Anatomy 0.000 description 55
- 239000002679 microRNA Substances 0.000 description 54
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 29
- 238000010586 diagram Methods 0.000 description 26
- 239000003550 marker Substances 0.000 description 22
- 239000002246 antineoplastic agent Substances 0.000 description 21
- 238000012360 testing method Methods 0.000 description 20
- 150000001875 compounds Chemical class 0.000 description 17
- 230000000694 effects Effects 0.000 description 17
- 241000699666 Mus <mouse, genus> Species 0.000 description 16
- 239000013642 negative control Substances 0.000 description 16
- 239000000523 sample Substances 0.000 description 15
- 230000004663 cell proliferation Effects 0.000 description 12
- 238000003556 assay Methods 0.000 description 11
- 238000001727 in vivo Methods 0.000 description 11
- 238000011529 RT qPCR Methods 0.000 description 10
- 230000006907 apoptotic process Effects 0.000 description 10
- 239000003112 inhibitor Substances 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 238000003384 imaging method Methods 0.000 description 9
- 230000005907 cancer growth Effects 0.000 description 8
- 238000004020 luminiscence type Methods 0.000 description 8
- 210000000056 organ Anatomy 0.000 description 8
- 238000010186 staining Methods 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 238000002054 transplantation Methods 0.000 description 8
- 230000012010 growth Effects 0.000 description 7
- 238000003753 real-time PCR Methods 0.000 description 7
- 108090000331 Firefly luciferases Proteins 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 108020004459 Small interfering RNA Proteins 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 230000009545 invasion Effects 0.000 description 6
- 230000035755 proliferation Effects 0.000 description 6
- 239000013598 vector Substances 0.000 description 6
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 5
- 230000001640 apoptogenic effect Effects 0.000 description 5
- 230000010261 cell growth Effects 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 108091029119 miR-34a stem-loop Proteins 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 230000001629 suppression Effects 0.000 description 5
- 102000013698 Cyclin-Dependent Kinase 6 Human genes 0.000 description 4
- 108010025468 Cyclin-Dependent Kinase 6 Proteins 0.000 description 4
- 108091030146 MiRBase Proteins 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 239000002502 liposome Substances 0.000 description 4
- 238000007447 staining method Methods 0.000 description 4
- 230000029663 wound healing Effects 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 238000000636 Northern blotting Methods 0.000 description 3
- 206010052428 Wound Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 241000021375 Xenogenes Species 0.000 description 3
- 230000012292 cell migration Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 210000004748 cultured cell Anatomy 0.000 description 3
- 238000004043 dyeing Methods 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 230000002431 foraging effect Effects 0.000 description 3
- 238000007901 in situ hybridization Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 238000002493 microarray Methods 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 230000005760 tumorsuppression Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 101001013208 Homo sapiens Mediator of RNA polymerase II transcription subunit 15 Proteins 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 102100029663 Mediator of RNA polymerase II transcription subunit 15 Human genes 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000009702 cancer cell proliferation Effects 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000008260 defense mechanism Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000010195 expression analysis Methods 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 239000012266 salt solution Substances 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 238000013042 tunel staining Methods 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 1
- 241000725101 Clea Species 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 238000007397 LAMP assay Methods 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 239000012098 Lipofectamine RNAiMAX Substances 0.000 description 1
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 108700011259 MicroRNAs Proteins 0.000 description 1
- 241000711408 Murine respirovirus Species 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 108091081021 Sense strand Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 241000710960 Sindbis virus Species 0.000 description 1
- 102000039471 Small Nuclear RNA Human genes 0.000 description 1
- 101150080074 TP53 gene Proteins 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000005415 bioluminescence Methods 0.000 description 1
- 230000029918 bioluminescence Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000004709 cell invasion Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 230000010094 cellular senescence Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012761 co-transfection Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000009650 gentamicin protection assay Methods 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 208000021601 lentivirus infection Diseases 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 239000002923 metal particle Substances 0.000 description 1
- 238000003253 miRNA assay Methods 0.000 description 1
- 108091007426 microRNA precursor Proteins 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 210000000287 oocyte Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 108700025694 p53 Genes Proteins 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- -1 potassium ferricyanide Chemical compound 0.000 description 1
- 239000000276 potassium ferrocyanide Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000010656 regulation of insulin secretion Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 108091029842 small nuclear ribonucleic acid Proteins 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- XOGGUFAVLNCTRS-UHFFFAOYSA-N tetrapotassium;iron(2+);hexacyanide Chemical compound [K+].[K+].[K+].[K+].[Fe+2].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-] XOGGUFAVLNCTRS-UHFFFAOYSA-N 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Plant Pathology (AREA)
- Hospice & Palliative Care (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
前記被験化合物非存在下での前記検体における前記miR−22の遺伝子転写物の発現量に対する、前記被験化合物存在下での前記検体における前記miR−22の遺伝子転写物の発現量を比較する工程と、
を含むことを特徴とする。
本発明の実施の形態1は、老化マーカーに関する。実施例において詳細に述べるが、本発明者が鋭意研究を行った結果、(hsa−)miR−22の遺伝子転写物は老化したヒト線維芽細胞において高発現していることが確認された。また、老化するに従って、(hsa−)miR−22の遺伝子転写物の発現量が増加するということもわかった。そこで、本実施の形態1に係る老化マーカーは、miR−22の遺伝子転写物を含む。詳細には、miR−22の遺伝子転写物は、配列番号1に記載の塩基配列からなるRNA、配列番号2に記載の塩基配列からなるRNA、および/または、配列番号3に記載の塩基配列からなるRNAを含む。なお、このような配列番号1に記載の塩基配列からなるRNA、配列番号2に記載の塩基配列からなるRNA、および/または、配列番号3に記載の塩基配列からなるRNAを含む本実施の形態1に係る老化マーカーには、Pre−hsa−miR−22および二本鎖hsa−miR−22も含有される。
本発明の実施の形態2は、老化抑制物質の評価方法に関する。詳細には、本実施の形態2は、被験化合物存在下および被験化合物非存在下での、検体における、miR−22の遺伝子転写物の発現量を測定する工程と、被験化合物非存在下での検体におけるmiR−22の遺伝子転写物の発現量に対する、被験化合物存在下での検体におけるmiR−22の遺伝子転写物の発現量を比較する工程と、を含む老化抑制物質の評価方法に関する。
本発明の実施の形態3は、miR−22の遺伝子転写物を有効成分として含有する癌抑制剤に関する。具体的には、miR−22の遺伝子転写物は、配列番号1に記載の塩基配列からなるRNA、配列番号2に記載の塩基配列からなるRNA、および/または、配列番号3に記載の塩基配列からなるRNAを含有し、細胞老化を促進させ、癌の浸潤および/または転移を抑制する。なお、実施の形態1および実施の形態2で述べた通り、miR−22の遺伝子転写物、または、配列番号1に記載の塩基配列からなるRNA、配列番号2に記載の塩基配列からなるRNAおよび/もしくは配列番号3に記載の塩基配列からなるRNAには、Pre−hsa−miR−22および二本鎖hsa−miR−22も含有される。
本実施例1では、若い細胞および老化細胞におけるヒト線維芽細胞のhsa−miR−22*の発現量に係る実施例について説明する。本発明者は、若いヒト線維芽細胞および老化ヒト線維芽細胞(若い細胞と比較して、分裂回数を繰り返した細胞)における、hsa−miR−22*の発現量を、定量的リアルタイムRT−PCR法によって調べた。以下、詳細に説明する。
本実施例2では、二本鎖hsa−miR−22をヒト線維芽細胞に導入した場合に係る実施例について説明する。本発明者は、二本鎖hsa−miR−22をヒト線維芽細胞(MRC−5細胞)に導入した場合、老化細胞において見られるような現象等が見られるか否かを調べた。以下、詳細に説明する。
本実施例3では、レンチウイルス感染によって、Pre−hsa−miR−22(図1参照)をヒト線維芽細胞(MRC−5細胞)に導入した場合に係る実施例について説明する。本発明者は、hsa−miR−22が成熟型(Mature)hsa−miR−22となる前のPre−hsa−miR−22をヒト線維芽細胞に導入した場合でも、細胞老化に特異的な現象(SA−β−gal活性および細胞増殖の阻害)が見られるか否かを確認した。
本実施例4では、癌細胞およびヒト正常線維芽細胞における、hsa−miR−22*の発現量に係る実施例について説明する。本発明者は、前述した実施例2および実施例3の結果であるmiR−22の細胞老化および細胞増殖阻害という特徴は、癌細胞とも関与しているのではないかと考えた。そこで、癌細胞およびヒト正常線維芽細胞におけるhsa−miR−22*の発現量を定量的リアルタイムRT−PCR分析によって調べ、比較した。以下、詳細に説明する。
本実施例5では、二本鎖hsa−miR−22を癌細胞に導入した場合に係る実施例について説明する。本発明者は、前述した実施例4の結果から、癌細胞における細胞増殖の現象は、miR−22の低発現量と関与しているのではないかと考えた。そこで、二本鎖hsa−miR−22を癌細胞に導入した場合、老化細胞において見られるような現象等が見られるか否かを調べた。以下、詳細に説明する。
本実施例6では、二本鎖hsa−miR−22を導入した癌細胞における細胞の浸潤性に係る実施例について説明する。本発明者は、前述した実施例5の結果から、二本鎖hsa−miR−22を導入することで、癌細胞の増殖の抑制のみならず、癌細胞の浸潤までも抑制できるのではないかと考えた。そこで、二本鎖hsa−miR−22を導入した癌細胞における細胞浸潤について調べた。以下、詳細に説明する。
本実施例7では、二本鎖hsa−miR−22を導入した癌細胞における細胞の遊送能に係る実施例(創傷治癒アッセイ、Wound-healing assay)について説明する。本発明者は、前述した実施例6の結果から示唆される二本鎖hsa−miR−22を導入することによる癌細胞の転移の抑制についても明確に調べるため、二本鎖hsa−miR−22を導入した癌細胞における細胞の遊送能について観察した。以下、詳細に説明する。
本発明者は、前述した実施例6および実施例7の結果から想到される、二本鎖hsa−miR−22の導入による癌の増殖、浸潤および転移の抑制効果をより確実に検証するために、乳癌転移モデルマウスによる腫瘍抑制試験を行った。まず、本実施例8では、該腫瘍抑制試験において使用するホタルルシフェラーゼ遺伝子を発現するMDA−MB−231−luc−D3H2LN乳癌細胞に二本鎖hsa−miR−22を導入した場合、前述した実施例5と同様に、老化細胞において見られるような現象等が見られるか否かを確認した。以下、詳細に説明する。
本実施例9では、前述した乳癌転移モデルマウスによる腫瘍抑制試験の詳細に係る実施例について説明する。本発明者は、in vivoでの二本鎖hsa−miR−22の導入(投与)による癌の増殖、浸潤および転移の抑制効果を検証するため、前述したホタルルシフェラーゼ遺伝子を発現するMDA−MB−231−luc−D3H2LN乳癌細胞を用い、モデルマウスでのホタルルシフェラーゼ遺伝子の発現解析を行った。以下、詳細に説明する。
本実施例10では、前述した実施例9でのin vivo乳癌転移モデルマウスにおける、免疫組織化学的な実施例について説明する。
本実施例11では、MultiTox assayによって、二本鎖hsa−miR−22を導入したSiHa細胞では、実施例10の結果によって示唆されるよう、本当にアポトーシスを引き起こしていないのかどうかについて検証した。
本実施例12でも、二本鎖hsa−miR−22を導入したSiHa細胞では本当にアポトーシスを引き起こしていないのかどうかについて検証するため、TUNEL染色法による実施例を行った。
Claims (4)
- miR−22の遺伝子転写物を有効成分として含有し、細胞老化を促進させ、癌の浸潤および/または転移を抑制し、
胃癌用細胞老化促進剤、子宮癌用細胞老化促進剤、咽頭癌用細胞老化促進剤、乳癌用細胞老化促進剤、子宮頸癌用細胞老化促進剤および/または結腸癌用細胞老化促進剤であることを特徴とする、癌疾患用細胞老化促進剤。 - 子宮頸癌用細胞老化促進剤および/または乳癌用細胞老化促進剤であることを特徴とする、請求項1に記載の癌疾患用細胞老化促進剤。
- 前記miR−22の遺伝子転写物は、配列番号1に記載の塩基配列からなるRNA、配列番号2に記載の塩基配列からなるRNA、および/または、配列番号3に記載の塩基配列からなるRNAを含むことを特徴とする、請求項1または2に記載の癌疾患用細胞老化促進剤。
- 前記miR−22の遺伝子転写物は、Pre−hsa−miR−22、および/または、二本鎖hsa−miR−22を含むことを特徴とする、請求項1または2に記載の癌疾患用細胞老化促進剤。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2011547497A JP5804459B2 (ja) | 2009-12-21 | 2010-12-15 | 癌疾患用細胞老化促進剤 |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009288707 | 2009-12-21 | ||
JP2009288707 | 2009-12-21 | ||
JP2010049928 | 2010-03-05 | ||
JP2010049928 | 2010-03-05 | ||
PCT/JP2010/072592 WO2011078037A1 (ja) | 2009-12-21 | 2010-12-15 | 老化マーカー、老化抑制物質の評価方法および癌抑制剤 |
JP2011547497A JP5804459B2 (ja) | 2009-12-21 | 2010-12-15 | 癌疾患用細胞老化促進剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPWO2011078037A1 JPWO2011078037A1 (ja) | 2013-05-02 |
JP5804459B2 true JP5804459B2 (ja) | 2015-11-04 |
Family
ID=44195567
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011547497A Active JP5804459B2 (ja) | 2009-12-21 | 2010-12-15 | 癌疾患用細胞老化促進剤 |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP2518144B1 (ja) |
JP (1) | JP5804459B2 (ja) |
WO (1) | WO2011078037A1 (ja) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL3019619T3 (pl) | 2013-07-11 | 2022-01-10 | Modernatx, Inc. | Kompozycje zawierające syntetyczne polinkleotydy kodujące białka powiązane z crispr i syntetyczne sgrna oraz sposoby ich stosowania |
US11311568B2 (en) | 2017-11-09 | 2022-04-26 | Purmx Therapeutics, Inc. | Therapeutic pharmaceutical composition for cancer including miRNA |
US20210024981A1 (en) * | 2018-09-07 | 2021-01-28 | Korea Advanced Institute Of Science And Technology | Composition for detecting dsrnas, comprising merocyanine compound and isomer thereof, and method for providing information for diagnosing cancer, by using dsrna expression analysis |
JP7191984B2 (ja) * | 2019-08-02 | 2022-12-19 | 株式会社東芝 | 分析方法及びキット |
EP4008793A4 (en) * | 2019-08-02 | 2023-04-12 | Kabushiki Kaisha Toshiba | ANALYTICAL METHOD AND KIT |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008519606A (ja) * | 2004-11-12 | 2008-06-12 | アンビオン インコーポレーティッド | miRNAおよびmiRNA阻害分子に関する方法および組成物 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060247193A1 (en) | 2003-02-10 | 2006-11-02 | National Institute Of Advanced Industrial Science And Technology | Regulation of gene expression by dna interference |
JP5435864B2 (ja) | 2004-05-28 | 2014-03-05 | アシュラジェン インコーポレイテッド | マイクロrnaに関与する方法および組成物 |
US20100021914A1 (en) * | 2006-11-23 | 2010-01-28 | Querdenker Aps | Oligonucleotides for modulating target rna activity |
JP4327888B1 (ja) | 2008-05-30 | 2009-09-09 | 株式会社東芝 | 音声音楽判定装置、音声音楽判定方法及び音声音楽判定用プログラム |
JP5273452B2 (ja) | 2008-08-21 | 2013-08-28 | ソニー株式会社 | 二次電池、負極、正極および電解質 |
-
2010
- 2010-12-15 EP EP10839270.5A patent/EP2518144B1/en active Active
- 2010-12-15 WO PCT/JP2010/072592 patent/WO2011078037A1/ja active Application Filing
- 2010-12-15 JP JP2011547497A patent/JP5804459B2/ja active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008519606A (ja) * | 2004-11-12 | 2008-06-12 | アンビオン インコーポレーティッド | miRNAおよびmiRNA阻害分子に関する方法および組成物 |
Non-Patent Citations (2)
Title |
---|
JPN6011012103; HE Chunlei.et al.: 'Functional elucidation of MiR-34 in osteosarcoma cells and primary tumor samples' Biochemical and Biophysical Research Communications Vol.388, 20091009, p.35-40 * |
JPN6011012104; LAFFERTY-WHYTE Kyle.et al.: 'Pathway analysis of senescence-associated miRNA targets reveals common processes to different senesc' Biochimica et Biophysica Acta Vol.1792, 200904, p.341-352 * |
Also Published As
Publication number | Publication date |
---|---|
EP2518144A4 (en) | 2013-05-15 |
EP2518144A1 (en) | 2012-10-31 |
WO2011078037A1 (ja) | 2011-06-30 |
JPWO2011078037A1 (ja) | 2013-05-02 |
EP2518144B1 (en) | 2015-08-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Jia et al. | Long non-coding RNA H19 regulates glioma angiogenesis and the biological behavior of glioma-associated endothelial cells by inhibiting microRNA-29a | |
Xu et al. | Regulation of HOXA11-AS/miR-214-3p/EZH2 axis on the growth, migration and invasion of glioma cells | |
Wang et al. | LncRNA GAS5 exacerbates renal tubular epithelial fibrosis by acting as a competing endogenous RNA of miR-96-5p | |
AU2010321555B2 (en) | Materials and methods useful for affecting tumor cell growth, migration and invasion | |
JP5931050B2 (ja) | miR−155によるミスマッチ修復およびゲノム安定性の調節に関連する材料および方法 | |
Huang et al. | MiR-137 suppresses migration and invasion by targeting EZH2-STAT3 signaling in human hepatocellular carcinoma | |
EP2077326A1 (en) | Novel nucleic acid | |
US20120184599A1 (en) | Use of MicroRNA for Treating Diseases Associated with a Dysfunction of the Cilia in Multiciliated Epithelial Cells | |
JPWO2008084319A1 (ja) | 新規核酸 | |
JP5804459B2 (ja) | 癌疾患用細胞老化促進剤 | |
JP2014500871A (ja) | マイクロrna−21、ミスマッチ修復および結腸直腸癌に関連する物質および方法 | |
JP6193269B2 (ja) | miR−199a−5p、その標的及び/又は阻害剤の、線維増殖障害の診断、予後予測及び治療のための使用 | |
Zhang et al. | Angiogenesis is inhibited by arsenic trioxide through downregulation of the CircHIPK3/miR-149-5p/FOXO1/VEGF functional module in rheumatoid arthritis | |
Huang et al. | MicroRNA-208a potentiates angiotensin II-triggered cardiac myoblasts apoptosis via inhibiting Nemo-like kinase (NLK) | |
KR101667169B1 (ko) | 암 치료제 | |
Danielson et al. | MiR-130b modulates the invasive, migratory, and metastatic behavior of leiomyosarcoma | |
WO2011111715A1 (ja) | 細胞周期を制御する核酸 | |
US9222089B2 (en) | Aging marker, method for evaluating aging inhibitor, and cancer inhibitor | |
CN107227362B (zh) | 一种与肝癌相关的基因及其应用 | |
US11965162B2 (en) | MicroRNA and inhibitors thereof and methods of treatment | |
JP5567555B2 (ja) | 頭頸部腫瘍増殖抑制剤 | |
KR102120659B1 (ko) | 난소과립막세포암 또는 자궁내막암의 진단 및 치료를 위한 마이크로rna-1236의 용도 | |
Yang et al. | MiR-509-5p improves the proliferative and invasive abilities of papillary thyroid carcinoma cells by inhibiting SFRP1 | |
Hei et al. | Circular RNA_0076977 contributes to oral squamous cell carcinoma progression through mediating microRNA-802 axis | |
JP2010030956A (ja) | 骨芽細胞分化促進剤及び抑制剤並びに骨形成促進剤、骨粗鬆症の治療薬、抗肥満薬及びスクリーニング方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20131129 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150210 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150410 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20150410 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20150818 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150824 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5804459 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |